Review




Structured Review

Bio-Rad ly6g gr1
Alox15 −/− mice are deficient in intramuscular 12/15-LOX-derived lipid mediators and display chronic low-grade muscle inflammation. A: Western blot analysis of the abundance of the 12/15-LOX protein in TA muscle homogenates from WT and Alox15 −/− mice. A spleen homogenate from a WT mouse served as a positive control. B: Densitometry quantification of the abundance of the 12/15-LOX protein in the TA muscle. Protein expression was normalized to GAPDH abundance. C: Alox1 5 mRNA expression in the TA muscle as determined by real-time quantitative reverse transcription PCR (RT-qPCR). Gene expression was normalized to Gapdh . D: Heatmap of the top 30 most differentially abundant lipid mediators TA muscle homogenates between WT and Alox15 −/− mice as identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). E-G: Quantification of the intramuscular concentration (pg/mg) of major 12/15-LOX metabolites including 12-hydroxy-eicosatetraenoic acid (12-HETE) ( E ), 15-hydroxy-eicosatetraenoic acid (15-HETE) ( F ), and 14-hydroxy-docosahexaenoic acid (14-HDoHE) ( G ) in TA muscle homogenates as determined by LC-MS/MS. H: TA muscle cross-sections were stained with primary antibodies against the neutrophil marker <t>GR1,</t> the pan monocyte/macrophage marker CD68, or the M2 macrophage marker CD163. Scale bars are 100 μm. I–K: Quantitative analysis of intramuscular numbers of neutrophils (GR1 + cells) ( I ), monocyte/macrophages (CD68 + cells) ( J ), and M2-like macrophages (CD68 + CD163 + cells) ( K ). L-M: Quantification of percentage TA muscle fiber type ( L ) and fiber type specific myofiber cross-sectional area (CSA) ( M ) as determined by MuscleJ 1.0.2 software. Bars show the mean ± SEM of 4–5 mice per group (biological replicates) with dots representing data from each individual mouse. P- values were determined by two-tailed unpaired t-tests. ∗ p < 0.05, ∗∗ p < 0.01 for WT vs. Alox15 −/− mice.
Ly6g Gr1, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 146 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ly6g gr1/product/Bio-Rad
Average 93 stars, based on 146 article reviews
ly6g gr1 - by Bioz Stars, 2026-04
93/100 stars

Images

1) Product Images from "Leukocyte-type 12/15-lipoxygenase is essential for timely inflammation-resolution and effective tissue regeneration following skeletal muscle injury"

Article Title: Leukocyte-type 12/15-lipoxygenase is essential for timely inflammation-resolution and effective tissue regeneration following skeletal muscle injury

Journal: Molecular Metabolism

doi: 10.1016/j.molmet.2025.102224

Alox15 −/− mice are deficient in intramuscular 12/15-LOX-derived lipid mediators and display chronic low-grade muscle inflammation. A: Western blot analysis of the abundance of the 12/15-LOX protein in TA muscle homogenates from WT and Alox15 −/− mice. A spleen homogenate from a WT mouse served as a positive control. B: Densitometry quantification of the abundance of the 12/15-LOX protein in the TA muscle. Protein expression was normalized to GAPDH abundance. C: Alox1 5 mRNA expression in the TA muscle as determined by real-time quantitative reverse transcription PCR (RT-qPCR). Gene expression was normalized to Gapdh . D: Heatmap of the top 30 most differentially abundant lipid mediators TA muscle homogenates between WT and Alox15 −/− mice as identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). E-G: Quantification of the intramuscular concentration (pg/mg) of major 12/15-LOX metabolites including 12-hydroxy-eicosatetraenoic acid (12-HETE) ( E ), 15-hydroxy-eicosatetraenoic acid (15-HETE) ( F ), and 14-hydroxy-docosahexaenoic acid (14-HDoHE) ( G ) in TA muscle homogenates as determined by LC-MS/MS. H: TA muscle cross-sections were stained with primary antibodies against the neutrophil marker GR1, the pan monocyte/macrophage marker CD68, or the M2 macrophage marker CD163. Scale bars are 100 μm. I–K: Quantitative analysis of intramuscular numbers of neutrophils (GR1 + cells) ( I ), monocyte/macrophages (CD68 + cells) ( J ), and M2-like macrophages (CD68 + CD163 + cells) ( K ). L-M: Quantification of percentage TA muscle fiber type ( L ) and fiber type specific myofiber cross-sectional area (CSA) ( M ) as determined by MuscleJ 1.0.2 software. Bars show the mean ± SEM of 4–5 mice per group (biological replicates) with dots representing data from each individual mouse. P- values were determined by two-tailed unpaired t-tests. ∗ p < 0.05, ∗∗ p < 0.01 for WT vs. Alox15 −/− mice.
Figure Legend Snippet: Alox15 −/− mice are deficient in intramuscular 12/15-LOX-derived lipid mediators and display chronic low-grade muscle inflammation. A: Western blot analysis of the abundance of the 12/15-LOX protein in TA muscle homogenates from WT and Alox15 −/− mice. A spleen homogenate from a WT mouse served as a positive control. B: Densitometry quantification of the abundance of the 12/15-LOX protein in the TA muscle. Protein expression was normalized to GAPDH abundance. C: Alox1 5 mRNA expression in the TA muscle as determined by real-time quantitative reverse transcription PCR (RT-qPCR). Gene expression was normalized to Gapdh . D: Heatmap of the top 30 most differentially abundant lipid mediators TA muscle homogenates between WT and Alox15 −/− mice as identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). E-G: Quantification of the intramuscular concentration (pg/mg) of major 12/15-LOX metabolites including 12-hydroxy-eicosatetraenoic acid (12-HETE) ( E ), 15-hydroxy-eicosatetraenoic acid (15-HETE) ( F ), and 14-hydroxy-docosahexaenoic acid (14-HDoHE) ( G ) in TA muscle homogenates as determined by LC-MS/MS. H: TA muscle cross-sections were stained with primary antibodies against the neutrophil marker GR1, the pan monocyte/macrophage marker CD68, or the M2 macrophage marker CD163. Scale bars are 100 μm. I–K: Quantitative analysis of intramuscular numbers of neutrophils (GR1 + cells) ( I ), monocyte/macrophages (CD68 + cells) ( J ), and M2-like macrophages (CD68 + CD163 + cells) ( K ). L-M: Quantification of percentage TA muscle fiber type ( L ) and fiber type specific myofiber cross-sectional area (CSA) ( M ) as determined by MuscleJ 1.0.2 software. Bars show the mean ± SEM of 4–5 mice per group (biological replicates) with dots representing data from each individual mouse. P- values were determined by two-tailed unpaired t-tests. ∗ p < 0.05, ∗∗ p < 0.01 for WT vs. Alox15 −/− mice.

Techniques Used: Derivative Assay, Western Blot, Positive Control, Expressing, Reverse Transcription, Quantitative RT-PCR, Gene Expression, Liquid Chromatography, Mass Spectrometry, Liquid Chromatography with Mass Spectroscopy, Concentration Assay, Staining, Marker, Software, Two Tailed Test

Leukocyte-type 12/15-LOX deficient mice display greater local inflammation and an imbalance of pro-inflammation vs. anti-inflammatory/pro-resolving lipid mediators following acute skeletal muscle injury. A-E: Tibialis anterior (TA) muscle mRNA expression of the pan myeloid cell marker CD11b ( Itgam ) ( A ), the pan monocyte/MФ marker F4/80 ( Adgre1 ) ( B ), the M2 MФ marker CD206 ( Mrc1 ) ( C ), the hematopoietic growth factor M-CSF ( Csf1 ) ( D ), and the hematopoietic growth factor GM-CSF ( Csf2 ) ( E ) in wild type (WT) and Alox15 −/− mice at day 0 (D0), day 3 (D3), day 5 (D5), and day 14 (D14) following myofiber injury induced by intramuscular injection of 50 μL of 1.2% barium chloride (BaCl 2 ). Expression of genes of interest was normalized to Gapdh . F: Immunofluorescence staining with primary antibodies against neutrophils (PMNs) (GR1), monocytes/MФ (CD68), and M2 MФ (CD163) in injured TA muscle of WT and Alox15 −/− mice on D3 and D5 post-injury. Cell nuclei were stained with DAPI and a primary antibody against laminin was used to identify muscle fiber boundaries. Scale bars are 100 μm. G-I : Quantification of PMNs (GR1 + cells/mm 2 ) ( G ), monocytes/MФ (CD68 + cells/mm 2 ) ( H ), and M2 MФ (CD68 + CD163 + cells/mm 2 ) ( I ) at D0, D3, and D5 post-injury in WT and Alox15 −/− mice. J-N: TA mRNA expression of major lipid mediator biosynthesis enzymes including COX-1 ( Ptgs1 ) ( J ), COX-2 ( Ptsg2 ) ( K ), 5-LOX ( Alox5 ) ( L ), 12-LOX ( Alox12 ) ( M ), and 15-LOX ( Alox15 ). O: Heatmap of the top 30 most differentially abundant lipid mediators between WT and Alox15 −/− mice as identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of TA muscle homogenates. P-Q: Quantification of major representative metabolites of the COX pathway (e.g., PGE 2 ) ( P ), 5-LOX pathway (e.g., 5-HETE) ( Q ), 12-LOX pathway (e.g., 14-HDoHE) ( R ), 15-LOX pathway (e.g., 17-HDoHE) ( S ), CYP pathway [e.g., 11(12)-EpETrE) ( T ), and downstream bioactive SPMs (e.g., RvD6) ( Q ). Bars show the mean ± SEM of 4–5 mice per group (biological replicates) with dots representing data from each individual mouse. P- values were determined by two-way ANOVA followed by Holm-Šídák post-hoc tests. ∗ p < 0.05 vs. D0 and # p < 0.05 for WT vs. Alox15 −/− mice.
Figure Legend Snippet: Leukocyte-type 12/15-LOX deficient mice display greater local inflammation and an imbalance of pro-inflammation vs. anti-inflammatory/pro-resolving lipid mediators following acute skeletal muscle injury. A-E: Tibialis anterior (TA) muscle mRNA expression of the pan myeloid cell marker CD11b ( Itgam ) ( A ), the pan monocyte/MФ marker F4/80 ( Adgre1 ) ( B ), the M2 MФ marker CD206 ( Mrc1 ) ( C ), the hematopoietic growth factor M-CSF ( Csf1 ) ( D ), and the hematopoietic growth factor GM-CSF ( Csf2 ) ( E ) in wild type (WT) and Alox15 −/− mice at day 0 (D0), day 3 (D3), day 5 (D5), and day 14 (D14) following myofiber injury induced by intramuscular injection of 50 μL of 1.2% barium chloride (BaCl 2 ). Expression of genes of interest was normalized to Gapdh . F: Immunofluorescence staining with primary antibodies against neutrophils (PMNs) (GR1), monocytes/MФ (CD68), and M2 MФ (CD163) in injured TA muscle of WT and Alox15 −/− mice on D3 and D5 post-injury. Cell nuclei were stained with DAPI and a primary antibody against laminin was used to identify muscle fiber boundaries. Scale bars are 100 μm. G-I : Quantification of PMNs (GR1 + cells/mm 2 ) ( G ), monocytes/MФ (CD68 + cells/mm 2 ) ( H ), and M2 MФ (CD68 + CD163 + cells/mm 2 ) ( I ) at D0, D3, and D5 post-injury in WT and Alox15 −/− mice. J-N: TA mRNA expression of major lipid mediator biosynthesis enzymes including COX-1 ( Ptgs1 ) ( J ), COX-2 ( Ptsg2 ) ( K ), 5-LOX ( Alox5 ) ( L ), 12-LOX ( Alox12 ) ( M ), and 15-LOX ( Alox15 ). O: Heatmap of the top 30 most differentially abundant lipid mediators between WT and Alox15 −/− mice as identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of TA muscle homogenates. P-Q: Quantification of major representative metabolites of the COX pathway (e.g., PGE 2 ) ( P ), 5-LOX pathway (e.g., 5-HETE) ( Q ), 12-LOX pathway (e.g., 14-HDoHE) ( R ), 15-LOX pathway (e.g., 17-HDoHE) ( S ), CYP pathway [e.g., 11(12)-EpETrE) ( T ), and downstream bioactive SPMs (e.g., RvD6) ( Q ). Bars show the mean ± SEM of 4–5 mice per group (biological replicates) with dots representing data from each individual mouse. P- values were determined by two-way ANOVA followed by Holm-Šídák post-hoc tests. ∗ p < 0.05 vs. D0 and # p < 0.05 for WT vs. Alox15 −/− mice.

Techniques Used: Expressing, Marker, Injection, Immunofluorescence, Staining, Liquid Chromatography, Mass Spectrometry, Liquid Chromatography with Mass Spectroscopy



Similar Products

93
Bio-Rad ly6g gr1
Alox15 −/− mice are deficient in intramuscular 12/15-LOX-derived lipid mediators and display chronic low-grade muscle inflammation. A: Western blot analysis of the abundance of the 12/15-LOX protein in TA muscle homogenates from WT and Alox15 −/− mice. A spleen homogenate from a WT mouse served as a positive control. B: Densitometry quantification of the abundance of the 12/15-LOX protein in the TA muscle. Protein expression was normalized to GAPDH abundance. C: Alox1 5 mRNA expression in the TA muscle as determined by real-time quantitative reverse transcription PCR (RT-qPCR). Gene expression was normalized to Gapdh . D: Heatmap of the top 30 most differentially abundant lipid mediators TA muscle homogenates between WT and Alox15 −/− mice as identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). E-G: Quantification of the intramuscular concentration (pg/mg) of major 12/15-LOX metabolites including 12-hydroxy-eicosatetraenoic acid (12-HETE) ( E ), 15-hydroxy-eicosatetraenoic acid (15-HETE) ( F ), and 14-hydroxy-docosahexaenoic acid (14-HDoHE) ( G ) in TA muscle homogenates as determined by LC-MS/MS. H: TA muscle cross-sections were stained with primary antibodies against the neutrophil marker <t>GR1,</t> the pan monocyte/macrophage marker CD68, or the M2 macrophage marker CD163. Scale bars are 100 μm. I–K: Quantitative analysis of intramuscular numbers of neutrophils (GR1 + cells) ( I ), monocyte/macrophages (CD68 + cells) ( J ), and M2-like macrophages (CD68 + CD163 + cells) ( K ). L-M: Quantification of percentage TA muscle fiber type ( L ) and fiber type specific myofiber cross-sectional area (CSA) ( M ) as determined by MuscleJ 1.0.2 software. Bars show the mean ± SEM of 4–5 mice per group (biological replicates) with dots representing data from each individual mouse. P- values were determined by two-tailed unpaired t-tests. ∗ p < 0.05, ∗∗ p < 0.01 for WT vs. Alox15 −/− mice.
Ly6g Gr1, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ly6g gr1/product/Bio-Rad
Average 93 stars, based on 1 article reviews
ly6g gr1 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

90
Becton Dickinson anti-mouse gr1(ly6g + ly6c) percp-cy 5.5
Alox15 −/− mice are deficient in intramuscular 12/15-LOX-derived lipid mediators and display chronic low-grade muscle inflammation. A: Western blot analysis of the abundance of the 12/15-LOX protein in TA muscle homogenates from WT and Alox15 −/− mice. A spleen homogenate from a WT mouse served as a positive control. B: Densitometry quantification of the abundance of the 12/15-LOX protein in the TA muscle. Protein expression was normalized to GAPDH abundance. C: Alox1 5 mRNA expression in the TA muscle as determined by real-time quantitative reverse transcription PCR (RT-qPCR). Gene expression was normalized to Gapdh . D: Heatmap of the top 30 most differentially abundant lipid mediators TA muscle homogenates between WT and Alox15 −/− mice as identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). E-G: Quantification of the intramuscular concentration (pg/mg) of major 12/15-LOX metabolites including 12-hydroxy-eicosatetraenoic acid (12-HETE) ( E ), 15-hydroxy-eicosatetraenoic acid (15-HETE) ( F ), and 14-hydroxy-docosahexaenoic acid (14-HDoHE) ( G ) in TA muscle homogenates as determined by LC-MS/MS. H: TA muscle cross-sections were stained with primary antibodies against the neutrophil marker <t>GR1,</t> the pan monocyte/macrophage marker CD68, or the M2 macrophage marker CD163. Scale bars are 100 μm. I–K: Quantitative analysis of intramuscular numbers of neutrophils (GR1 + cells) ( I ), monocyte/macrophages (CD68 + cells) ( J ), and M2-like macrophages (CD68 + CD163 + cells) ( K ). L-M: Quantification of percentage TA muscle fiber type ( L ) and fiber type specific myofiber cross-sectional area (CSA) ( M ) as determined by MuscleJ 1.0.2 software. Bars show the mean ± SEM of 4–5 mice per group (biological replicates) with dots representing data from each individual mouse. P- values were determined by two-tailed unpaired t-tests. ∗ p < 0.05, ∗∗ p < 0.01 for WT vs. Alox15 −/− mice.
Anti Mouse Gr1(Ly6g + Ly6c) Percp Cy 5.5, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-mouse gr1(ly6g + ly6c) percp-cy 5.5/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
anti-mouse gr1(ly6g + ly6c) percp-cy 5.5 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

94
Bio X Cell anti gr1 rb6 8c5
Alox15 −/− mice are deficient in intramuscular 12/15-LOX-derived lipid mediators and display chronic low-grade muscle inflammation. A: Western blot analysis of the abundance of the 12/15-LOX protein in TA muscle homogenates from WT and Alox15 −/− mice. A spleen homogenate from a WT mouse served as a positive control. B: Densitometry quantification of the abundance of the 12/15-LOX protein in the TA muscle. Protein expression was normalized to GAPDH abundance. C: Alox1 5 mRNA expression in the TA muscle as determined by real-time quantitative reverse transcription PCR (RT-qPCR). Gene expression was normalized to Gapdh . D: Heatmap of the top 30 most differentially abundant lipid mediators TA muscle homogenates between WT and Alox15 −/− mice as identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). E-G: Quantification of the intramuscular concentration (pg/mg) of major 12/15-LOX metabolites including 12-hydroxy-eicosatetraenoic acid (12-HETE) ( E ), 15-hydroxy-eicosatetraenoic acid (15-HETE) ( F ), and 14-hydroxy-docosahexaenoic acid (14-HDoHE) ( G ) in TA muscle homogenates as determined by LC-MS/MS. H: TA muscle cross-sections were stained with primary antibodies against the neutrophil marker <t>GR1,</t> the pan monocyte/macrophage marker CD68, or the M2 macrophage marker CD163. Scale bars are 100 μm. I–K: Quantitative analysis of intramuscular numbers of neutrophils (GR1 + cells) ( I ), monocyte/macrophages (CD68 + cells) ( J ), and M2-like macrophages (CD68 + CD163 + cells) ( K ). L-M: Quantification of percentage TA muscle fiber type ( L ) and fiber type specific myofiber cross-sectional area (CSA) ( M ) as determined by MuscleJ 1.0.2 software. Bars show the mean ± SEM of 4–5 mice per group (biological replicates) with dots representing data from each individual mouse. P- values were determined by two-tailed unpaired t-tests. ∗ p < 0.05, ∗∗ p < 0.01 for WT vs. Alox15 −/− mice.
Anti Gr1 Rb6 8c5, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti gr1 rb6 8c5/product/Bio X Cell
Average 94 stars, based on 1 article reviews
anti gr1 rb6 8c5 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

90
Thermo Fisher gr1(ly6g)-pe 12-9668-82 antibody
Alox15 −/− mice are deficient in intramuscular 12/15-LOX-derived lipid mediators and display chronic low-grade muscle inflammation. A: Western blot analysis of the abundance of the 12/15-LOX protein in TA muscle homogenates from WT and Alox15 −/− mice. A spleen homogenate from a WT mouse served as a positive control. B: Densitometry quantification of the abundance of the 12/15-LOX protein in the TA muscle. Protein expression was normalized to GAPDH abundance. C: Alox1 5 mRNA expression in the TA muscle as determined by real-time quantitative reverse transcription PCR (RT-qPCR). Gene expression was normalized to Gapdh . D: Heatmap of the top 30 most differentially abundant lipid mediators TA muscle homogenates between WT and Alox15 −/− mice as identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). E-G: Quantification of the intramuscular concentration (pg/mg) of major 12/15-LOX metabolites including 12-hydroxy-eicosatetraenoic acid (12-HETE) ( E ), 15-hydroxy-eicosatetraenoic acid (15-HETE) ( F ), and 14-hydroxy-docosahexaenoic acid (14-HDoHE) ( G ) in TA muscle homogenates as determined by LC-MS/MS. H: TA muscle cross-sections were stained with primary antibodies against the neutrophil marker <t>GR1,</t> the pan monocyte/macrophage marker CD68, or the M2 macrophage marker CD163. Scale bars are 100 μm. I–K: Quantitative analysis of intramuscular numbers of neutrophils (GR1 + cells) ( I ), monocyte/macrophages (CD68 + cells) ( J ), and M2-like macrophages (CD68 + CD163 + cells) ( K ). L-M: Quantification of percentage TA muscle fiber type ( L ) and fiber type specific myofiber cross-sectional area (CSA) ( M ) as determined by MuscleJ 1.0.2 software. Bars show the mean ± SEM of 4–5 mice per group (biological replicates) with dots representing data from each individual mouse. P- values were determined by two-tailed unpaired t-tests. ∗ p < 0.05, ∗∗ p < 0.01 for WT vs. Alox15 −/− mice.
Gr1(Ly6g) Pe 12 9668 82 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gr1(ly6g)-pe 12-9668-82 antibody/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
gr1(ly6g)-pe 12-9668-82 antibody - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Thermo Fisher anti ly6g (gr1)
Alox15 −/− mice are deficient in intramuscular 12/15-LOX-derived lipid mediators and display chronic low-grade muscle inflammation. A: Western blot analysis of the abundance of the 12/15-LOX protein in TA muscle homogenates from WT and Alox15 −/− mice. A spleen homogenate from a WT mouse served as a positive control. B: Densitometry quantification of the abundance of the 12/15-LOX protein in the TA muscle. Protein expression was normalized to GAPDH abundance. C: Alox1 5 mRNA expression in the TA muscle as determined by real-time quantitative reverse transcription PCR (RT-qPCR). Gene expression was normalized to Gapdh . D: Heatmap of the top 30 most differentially abundant lipid mediators TA muscle homogenates between WT and Alox15 −/− mice as identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). E-G: Quantification of the intramuscular concentration (pg/mg) of major 12/15-LOX metabolites including 12-hydroxy-eicosatetraenoic acid (12-HETE) ( E ), 15-hydroxy-eicosatetraenoic acid (15-HETE) ( F ), and 14-hydroxy-docosahexaenoic acid (14-HDoHE) ( G ) in TA muscle homogenates as determined by LC-MS/MS. H: TA muscle cross-sections were stained with primary antibodies against the neutrophil marker <t>GR1,</t> the pan monocyte/macrophage marker CD68, or the M2 macrophage marker CD163. Scale bars are 100 μm. I–K: Quantitative analysis of intramuscular numbers of neutrophils (GR1 + cells) ( I ), monocyte/macrophages (CD68 + cells) ( J ), and M2-like macrophages (CD68 + CD163 + cells) ( K ). L-M: Quantification of percentage TA muscle fiber type ( L ) and fiber type specific myofiber cross-sectional area (CSA) ( M ) as determined by MuscleJ 1.0.2 software. Bars show the mean ± SEM of 4–5 mice per group (biological replicates) with dots representing data from each individual mouse. P- values were determined by two-tailed unpaired t-tests. ∗ p < 0.05, ∗∗ p < 0.01 for WT vs. Alox15 −/− mice.
Anti Ly6g (Gr1), supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti ly6g (gr1)/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
anti ly6g (gr1) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

94
Bio X Cell be0089 invivomab anti mouse ly6g ly6c gr1 bio x cell
Alox15 −/− mice are deficient in intramuscular 12/15-LOX-derived lipid mediators and display chronic low-grade muscle inflammation. A: Western blot analysis of the abundance of the 12/15-LOX protein in TA muscle homogenates from WT and Alox15 −/− mice. A spleen homogenate from a WT mouse served as a positive control. B: Densitometry quantification of the abundance of the 12/15-LOX protein in the TA muscle. Protein expression was normalized to GAPDH abundance. C: Alox1 5 mRNA expression in the TA muscle as determined by real-time quantitative reverse transcription PCR (RT-qPCR). Gene expression was normalized to Gapdh . D: Heatmap of the top 30 most differentially abundant lipid mediators TA muscle homogenates between WT and Alox15 −/− mice as identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). E-G: Quantification of the intramuscular concentration (pg/mg) of major 12/15-LOX metabolites including 12-hydroxy-eicosatetraenoic acid (12-HETE) ( E ), 15-hydroxy-eicosatetraenoic acid (15-HETE) ( F ), and 14-hydroxy-docosahexaenoic acid (14-HDoHE) ( G ) in TA muscle homogenates as determined by LC-MS/MS. H: TA muscle cross-sections were stained with primary antibodies against the neutrophil marker <t>GR1,</t> the pan monocyte/macrophage marker CD68, or the M2 macrophage marker CD163. Scale bars are 100 μm. I–K: Quantitative analysis of intramuscular numbers of neutrophils (GR1 + cells) ( I ), monocyte/macrophages (CD68 + cells) ( J ), and M2-like macrophages (CD68 + CD163 + cells) ( K ). L-M: Quantification of percentage TA muscle fiber type ( L ) and fiber type specific myofiber cross-sectional area (CSA) ( M ) as determined by MuscleJ 1.0.2 software. Bars show the mean ± SEM of 4–5 mice per group (biological replicates) with dots representing data from each individual mouse. P- values were determined by two-tailed unpaired t-tests. ∗ p < 0.05, ∗∗ p < 0.01 for WT vs. Alox15 −/− mice.
Be0089 Invivomab Anti Mouse Ly6g Ly6c Gr1 Bio X Cell, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/be0089 invivomab anti mouse ly6g ly6c gr1 bio x cell/product/Bio X Cell
Average 94 stars, based on 1 article reviews
be0089 invivomab anti mouse ly6g ly6c gr1 bio x cell - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

90
Thermo Fisher anti-ly6g (gr1
HEM reduces edema and neutrophilic inflammation in the ALI model. Histological analysis ( A , B ), protein exudate in the BALF ( C ), lung wet/dry weight ratio ( D ), and lung immunofluorescence ( E ) (magnification: 100×). Protein was quantified in the BALF, and the lung was used to determine the weight/dry ratio and morphometric and immunofluorescence analysis. For immunofluorescence analysis, neutrophils in lung tissue were labeled with anti-Ly-6G <t>(GR1</t> + cells) and DAPI. The photomicrographs of histology and immunofluorescence procedures are representative of five animals per group. The data are presented as ± SEM. Data were analyzed using one-way ANOVA followed by Bonferroni post-test. * p < 0.05, ** p < 0.005, *** p < 0.001 or **** p < 0.0001. BASAL (no LPS-challenged), ALI (LPS-challenged), DEXA (LPS-challenged and orally treated with dexamethasone), HEM (LPS-challenged and orally treated with HEM).
Anti Ly6g (Gr1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-ly6g (gr1/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
anti-ly6g (gr1 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Thermo Fisher anti-ly6g (gr1) ebioscience fitc cat# 11-5931-82
HEM reduces edema and neutrophilic inflammation in the ALI model. Histological analysis ( A , B ), protein exudate in the BALF ( C ), lung wet/dry weight ratio ( D ), and lung immunofluorescence ( E ) (magnification: 100×). Protein was quantified in the BALF, and the lung was used to determine the weight/dry ratio and morphometric and immunofluorescence analysis. For immunofluorescence analysis, neutrophils in lung tissue were labeled with anti-Ly-6G <t>(GR1</t> + cells) and DAPI. The photomicrographs of histology and immunofluorescence procedures are representative of five animals per group. The data are presented as ± SEM. Data were analyzed using one-way ANOVA followed by Bonferroni post-test. * p < 0.05, ** p < 0.005, *** p < 0.001 or **** p < 0.0001. BASAL (no LPS-challenged), ALI (LPS-challenged), DEXA (LPS-challenged and orally treated with dexamethasone), HEM (LPS-challenged and orally treated with HEM).
Anti Ly6g (Gr1) Ebioscience Fitc Cat# 11 5931 82, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-ly6g (gr1) ebioscience fitc cat# 11-5931-82/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
anti-ly6g (gr1) ebioscience fitc cat# 11-5931-82 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Thermo Fisher anti-mouse ly6g/ly6c(gr1) pe-cyanine7
HEM reduces edema and neutrophilic inflammation in the ALI model. Histological analysis ( A , B ), protein exudate in the BALF ( C ), lung wet/dry weight ratio ( D ), and lung immunofluorescence ( E ) (magnification: 100×). Protein was quantified in the BALF, and the lung was used to determine the weight/dry ratio and morphometric and immunofluorescence analysis. For immunofluorescence analysis, neutrophils in lung tissue were labeled with anti-Ly-6G <t>(GR1</t> + cells) and DAPI. The photomicrographs of histology and immunofluorescence procedures are representative of five animals per group. The data are presented as ± SEM. Data were analyzed using one-way ANOVA followed by Bonferroni post-test. * p < 0.05, ** p < 0.005, *** p < 0.001 or **** p < 0.0001. BASAL (no LPS-challenged), ALI (LPS-challenged), DEXA (LPS-challenged and orally treated with dexamethasone), HEM (LPS-challenged and orally treated with HEM).
Anti Mouse Ly6g/Ly6c(Gr1) Pe Cyanine7, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-mouse ly6g/ly6c(gr1) pe-cyanine7/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
anti-mouse ly6g/ly6c(gr1) pe-cyanine7 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Alox15 −/− mice are deficient in intramuscular 12/15-LOX-derived lipid mediators and display chronic low-grade muscle inflammation. A: Western blot analysis of the abundance of the 12/15-LOX protein in TA muscle homogenates from WT and Alox15 −/− mice. A spleen homogenate from a WT mouse served as a positive control. B: Densitometry quantification of the abundance of the 12/15-LOX protein in the TA muscle. Protein expression was normalized to GAPDH abundance. C: Alox1 5 mRNA expression in the TA muscle as determined by real-time quantitative reverse transcription PCR (RT-qPCR). Gene expression was normalized to Gapdh . D: Heatmap of the top 30 most differentially abundant lipid mediators TA muscle homogenates between WT and Alox15 −/− mice as identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). E-G: Quantification of the intramuscular concentration (pg/mg) of major 12/15-LOX metabolites including 12-hydroxy-eicosatetraenoic acid (12-HETE) ( E ), 15-hydroxy-eicosatetraenoic acid (15-HETE) ( F ), and 14-hydroxy-docosahexaenoic acid (14-HDoHE) ( G ) in TA muscle homogenates as determined by LC-MS/MS. H: TA muscle cross-sections were stained with primary antibodies against the neutrophil marker GR1, the pan monocyte/macrophage marker CD68, or the M2 macrophage marker CD163. Scale bars are 100 μm. I–K: Quantitative analysis of intramuscular numbers of neutrophils (GR1 + cells) ( I ), monocyte/macrophages (CD68 + cells) ( J ), and M2-like macrophages (CD68 + CD163 + cells) ( K ). L-M: Quantification of percentage TA muscle fiber type ( L ) and fiber type specific myofiber cross-sectional area (CSA) ( M ) as determined by MuscleJ 1.0.2 software. Bars show the mean ± SEM of 4–5 mice per group (biological replicates) with dots representing data from each individual mouse. P- values were determined by two-tailed unpaired t-tests. ∗ p < 0.05, ∗∗ p < 0.01 for WT vs. Alox15 −/− mice.

Journal: Molecular Metabolism

Article Title: Leukocyte-type 12/15-lipoxygenase is essential for timely inflammation-resolution and effective tissue regeneration following skeletal muscle injury

doi: 10.1016/j.molmet.2025.102224

Figure Lengend Snippet: Alox15 −/− mice are deficient in intramuscular 12/15-LOX-derived lipid mediators and display chronic low-grade muscle inflammation. A: Western blot analysis of the abundance of the 12/15-LOX protein in TA muscle homogenates from WT and Alox15 −/− mice. A spleen homogenate from a WT mouse served as a positive control. B: Densitometry quantification of the abundance of the 12/15-LOX protein in the TA muscle. Protein expression was normalized to GAPDH abundance. C: Alox1 5 mRNA expression in the TA muscle as determined by real-time quantitative reverse transcription PCR (RT-qPCR). Gene expression was normalized to Gapdh . D: Heatmap of the top 30 most differentially abundant lipid mediators TA muscle homogenates between WT and Alox15 −/− mice as identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). E-G: Quantification of the intramuscular concentration (pg/mg) of major 12/15-LOX metabolites including 12-hydroxy-eicosatetraenoic acid (12-HETE) ( E ), 15-hydroxy-eicosatetraenoic acid (15-HETE) ( F ), and 14-hydroxy-docosahexaenoic acid (14-HDoHE) ( G ) in TA muscle homogenates as determined by LC-MS/MS. H: TA muscle cross-sections were stained with primary antibodies against the neutrophil marker GR1, the pan monocyte/macrophage marker CD68, or the M2 macrophage marker CD163. Scale bars are 100 μm. I–K: Quantitative analysis of intramuscular numbers of neutrophils (GR1 + cells) ( I ), monocyte/macrophages (CD68 + cells) ( J ), and M2-like macrophages (CD68 + CD163 + cells) ( K ). L-M: Quantification of percentage TA muscle fiber type ( L ) and fiber type specific myofiber cross-sectional area (CSA) ( M ) as determined by MuscleJ 1.0.2 software. Bars show the mean ± SEM of 4–5 mice per group (biological replicates) with dots representing data from each individual mouse. P- values were determined by two-tailed unpaired t-tests. ∗ p < 0.05, ∗∗ p < 0.01 for WT vs. Alox15 −/− mice.

Article Snippet: Primary antibodies used include MyHC type I [Developmental Studies Hybridoma Bank (DSHB), BA-D5c, 1:100], MyHC type IIA (DSHB, SC-71c, 1:100), MyHC type IIB (DSHB, BF–F3c, 1:100), eMHC (DSHB, F1.652s, 1:20), Ly6G (GR1) (Bio-Rad, MCA2387, 1:50), CD68 (Bio-Rad, MCA1957, 1:200), CD163 (Santa Cruz, sc-58965, 1:200), and laminin (Abcam, ab7463, 1:200).

Techniques: Derivative Assay, Western Blot, Positive Control, Expressing, Reverse Transcription, Quantitative RT-PCR, Gene Expression, Liquid Chromatography, Mass Spectrometry, Liquid Chromatography with Mass Spectroscopy, Concentration Assay, Staining, Marker, Software, Two Tailed Test

Leukocyte-type 12/15-LOX deficient mice display greater local inflammation and an imbalance of pro-inflammation vs. anti-inflammatory/pro-resolving lipid mediators following acute skeletal muscle injury. A-E: Tibialis anterior (TA) muscle mRNA expression of the pan myeloid cell marker CD11b ( Itgam ) ( A ), the pan monocyte/MФ marker F4/80 ( Adgre1 ) ( B ), the M2 MФ marker CD206 ( Mrc1 ) ( C ), the hematopoietic growth factor M-CSF ( Csf1 ) ( D ), and the hematopoietic growth factor GM-CSF ( Csf2 ) ( E ) in wild type (WT) and Alox15 −/− mice at day 0 (D0), day 3 (D3), day 5 (D5), and day 14 (D14) following myofiber injury induced by intramuscular injection of 50 μL of 1.2% barium chloride (BaCl 2 ). Expression of genes of interest was normalized to Gapdh . F: Immunofluorescence staining with primary antibodies against neutrophils (PMNs) (GR1), monocytes/MФ (CD68), and M2 MФ (CD163) in injured TA muscle of WT and Alox15 −/− mice on D3 and D5 post-injury. Cell nuclei were stained with DAPI and a primary antibody against laminin was used to identify muscle fiber boundaries. Scale bars are 100 μm. G-I : Quantification of PMNs (GR1 + cells/mm 2 ) ( G ), monocytes/MФ (CD68 + cells/mm 2 ) ( H ), and M2 MФ (CD68 + CD163 + cells/mm 2 ) ( I ) at D0, D3, and D5 post-injury in WT and Alox15 −/− mice. J-N: TA mRNA expression of major lipid mediator biosynthesis enzymes including COX-1 ( Ptgs1 ) ( J ), COX-2 ( Ptsg2 ) ( K ), 5-LOX ( Alox5 ) ( L ), 12-LOX ( Alox12 ) ( M ), and 15-LOX ( Alox15 ). O: Heatmap of the top 30 most differentially abundant lipid mediators between WT and Alox15 −/− mice as identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of TA muscle homogenates. P-Q: Quantification of major representative metabolites of the COX pathway (e.g., PGE 2 ) ( P ), 5-LOX pathway (e.g., 5-HETE) ( Q ), 12-LOX pathway (e.g., 14-HDoHE) ( R ), 15-LOX pathway (e.g., 17-HDoHE) ( S ), CYP pathway [e.g., 11(12)-EpETrE) ( T ), and downstream bioactive SPMs (e.g., RvD6) ( Q ). Bars show the mean ± SEM of 4–5 mice per group (biological replicates) with dots representing data from each individual mouse. P- values were determined by two-way ANOVA followed by Holm-Šídák post-hoc tests. ∗ p < 0.05 vs. D0 and # p < 0.05 for WT vs. Alox15 −/− mice.

Journal: Molecular Metabolism

Article Title: Leukocyte-type 12/15-lipoxygenase is essential for timely inflammation-resolution and effective tissue regeneration following skeletal muscle injury

doi: 10.1016/j.molmet.2025.102224

Figure Lengend Snippet: Leukocyte-type 12/15-LOX deficient mice display greater local inflammation and an imbalance of pro-inflammation vs. anti-inflammatory/pro-resolving lipid mediators following acute skeletal muscle injury. A-E: Tibialis anterior (TA) muscle mRNA expression of the pan myeloid cell marker CD11b ( Itgam ) ( A ), the pan monocyte/MФ marker F4/80 ( Adgre1 ) ( B ), the M2 MФ marker CD206 ( Mrc1 ) ( C ), the hematopoietic growth factor M-CSF ( Csf1 ) ( D ), and the hematopoietic growth factor GM-CSF ( Csf2 ) ( E ) in wild type (WT) and Alox15 −/− mice at day 0 (D0), day 3 (D3), day 5 (D5), and day 14 (D14) following myofiber injury induced by intramuscular injection of 50 μL of 1.2% barium chloride (BaCl 2 ). Expression of genes of interest was normalized to Gapdh . F: Immunofluorescence staining with primary antibodies against neutrophils (PMNs) (GR1), monocytes/MФ (CD68), and M2 MФ (CD163) in injured TA muscle of WT and Alox15 −/− mice on D3 and D5 post-injury. Cell nuclei were stained with DAPI and a primary antibody against laminin was used to identify muscle fiber boundaries. Scale bars are 100 μm. G-I : Quantification of PMNs (GR1 + cells/mm 2 ) ( G ), monocytes/MФ (CD68 + cells/mm 2 ) ( H ), and M2 MФ (CD68 + CD163 + cells/mm 2 ) ( I ) at D0, D3, and D5 post-injury in WT and Alox15 −/− mice. J-N: TA mRNA expression of major lipid mediator biosynthesis enzymes including COX-1 ( Ptgs1 ) ( J ), COX-2 ( Ptsg2 ) ( K ), 5-LOX ( Alox5 ) ( L ), 12-LOX ( Alox12 ) ( M ), and 15-LOX ( Alox15 ). O: Heatmap of the top 30 most differentially abundant lipid mediators between WT and Alox15 −/− mice as identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of TA muscle homogenates. P-Q: Quantification of major representative metabolites of the COX pathway (e.g., PGE 2 ) ( P ), 5-LOX pathway (e.g., 5-HETE) ( Q ), 12-LOX pathway (e.g., 14-HDoHE) ( R ), 15-LOX pathway (e.g., 17-HDoHE) ( S ), CYP pathway [e.g., 11(12)-EpETrE) ( T ), and downstream bioactive SPMs (e.g., RvD6) ( Q ). Bars show the mean ± SEM of 4–5 mice per group (biological replicates) with dots representing data from each individual mouse. P- values were determined by two-way ANOVA followed by Holm-Šídák post-hoc tests. ∗ p < 0.05 vs. D0 and # p < 0.05 for WT vs. Alox15 −/− mice.

Article Snippet: Primary antibodies used include MyHC type I [Developmental Studies Hybridoma Bank (DSHB), BA-D5c, 1:100], MyHC type IIA (DSHB, SC-71c, 1:100), MyHC type IIB (DSHB, BF–F3c, 1:100), eMHC (DSHB, F1.652s, 1:20), Ly6G (GR1) (Bio-Rad, MCA2387, 1:50), CD68 (Bio-Rad, MCA1957, 1:200), CD163 (Santa Cruz, sc-58965, 1:200), and laminin (Abcam, ab7463, 1:200).

Techniques: Expressing, Marker, Injection, Immunofluorescence, Staining, Liquid Chromatography, Mass Spectrometry, Liquid Chromatography with Mass Spectroscopy

HEM reduces edema and neutrophilic inflammation in the ALI model. Histological analysis ( A , B ), protein exudate in the BALF ( C ), lung wet/dry weight ratio ( D ), and lung immunofluorescence ( E ) (magnification: 100×). Protein was quantified in the BALF, and the lung was used to determine the weight/dry ratio and morphometric and immunofluorescence analysis. For immunofluorescence analysis, neutrophils in lung tissue were labeled with anti-Ly-6G (GR1 + cells) and DAPI. The photomicrographs of histology and immunofluorescence procedures are representative of five animals per group. The data are presented as ± SEM. Data were analyzed using one-way ANOVA followed by Bonferroni post-test. * p < 0.05, ** p < 0.005, *** p < 0.001 or **** p < 0.0001. BASAL (no LPS-challenged), ALI (LPS-challenged), DEXA (LPS-challenged and orally treated with dexamethasone), HEM (LPS-challenged and orally treated with HEM).

Journal: Pharmaceuticals

Article Title: Musa paradisiaca L. Inflorescence Abrogates Neutrophil Activation by Downregulating TLR4/NF-KB Signaling Pathway in LPS-Induced Acute Lung Injury Model

doi: 10.3390/ph18010008

Figure Lengend Snippet: HEM reduces edema and neutrophilic inflammation in the ALI model. Histological analysis ( A , B ), protein exudate in the BALF ( C ), lung wet/dry weight ratio ( D ), and lung immunofluorescence ( E ) (magnification: 100×). Protein was quantified in the BALF, and the lung was used to determine the weight/dry ratio and morphometric and immunofluorescence analysis. For immunofluorescence analysis, neutrophils in lung tissue were labeled with anti-Ly-6G (GR1 + cells) and DAPI. The photomicrographs of histology and immunofluorescence procedures are representative of five animals per group. The data are presented as ± SEM. Data were analyzed using one-way ANOVA followed by Bonferroni post-test. * p < 0.05, ** p < 0.005, *** p < 0.001 or **** p < 0.0001. BASAL (no LPS-challenged), ALI (LPS-challenged), DEXA (LPS-challenged and orally treated with dexamethasone), HEM (LPS-challenged and orally treated with HEM).

Article Snippet: The slides with the lung tissue were washed twice for 5 min in PBS with 0.025% Triton X-100 and blocked in 2% BSA for 2 h. Then, slides were incubated with anti-Ly6G (GR1) (eBioscience FITC CAT# 11-5931-82) and mounted in DAPI Fluoromount-G (REF 0100-20 Southern Biotech, Birmingham, AL, USA).

Techniques: Immunofluorescence, Labeling